Beyond tumor‑associated macrophages involved in spheroid formation and dissemination: Novel insights for ovarian cancer therapy (Review)

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI

Bast RC, Han CY, Lu Z and Lu KH: Next steps in the early detection of ovarian cancer. Commun Med (Lond). 1:362021. View Article : Google Scholar : PubMed/NCBI

Yang L, Xie HJ, Li YY, Wang X, Liu XX and Mai J: Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (review). Oncol Rep. 47:822022. View Article : Google Scholar

Almeida-Nunes DL, Mendes-Frias A, Silvestre R, Dinis-Oliveira RJ and Ricardo S: Immune tumor microenvironment in ovarian cancer ascites. Int J Mol Sci. 23:106922022. View Article : Google Scholar : PubMed/NCBI

Huang H, Li YJ, Lan CY, Huang QD, Feng YL, Huang YW and Liu JH: Clinical significance of ascites in epithelial ovarian cancer. Neoplasma. 60:546–552. 2013. View Article : Google Scholar : PubMed/NCBI

Kim S, Kim B and Song YS: Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 107:1173–1178. 2016. View Article : Google Scholar : PubMed/NCBI

Quan Q, Zhou S, Liu Y, Yin W, Liao Q, Ren S, Zhang F, Meng Y and Mu X: Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer. J Obstet Gynaecol Res. 47:1527–1535. 2021. View Article : Google Scholar : PubMed/NCBI

Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS and Donini A: Malignant ascites: Pathophysiology and treatment. Int J Clin Oncol. 18:1–9. 2013. View Article : Google Scholar

Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST and Mok SC: Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: Cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 309:C444–C456. 2015. View Article : Google Scholar : PubMed/NCBI

Al Habyan S, Kalos C, Szymborski J and McCaffrey L: Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer. Oncogene. 37:5127–5135. 2018. View Article : Google Scholar : PubMed/NCBI

Ahmed N and Stenvers KL: Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research. Front Oncol. 3:2562013. View Article : Google Scholar : PubMed/NCBI

Dhaliwal D and Shepherd TG: Molecular and cellular mechanisms controlling integrin-mediated cell adhesion and tumor progression in ovarian cancer metastasis: A review. Clin Exp Metastasis. 39:291–301. 2022. View Article : Google Scholar :

Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S and Müller R: The unique molecular and cellular microenvironment of ovarian cancer. Front Oncol. 7:242017. View Article : Google Scholar : PubMed/NCBI

Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, et al: Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 216:688–703. 2019. View Article : Google Scholar : PubMed/NCBI

Pan Y, Yu Y, Wang X and Zhang T: Tumor-associated macrophages in tumor immunity. Front Immunol. 11:5830842020. View Article : Google Scholar : PubMed/NCBI

Long L, Hu Y, Long T, Lu X, Tuo Y, Li Y and Ke Z: Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoelomic metastasis of ovarian cancer. J Immunother Cancer. 9:e0039732021. View Article : Google Scholar

Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G and Min W: Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 126:4157–4173. 2016. View Article : Google Scholar : PubMed/NCBI

Song M, Yeku OO, Rafiq S, Purdon T, Dong X, Zhu L, Zhang T, Wang H, Yu Z, Mai J, et al: Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat Commun. 11:62982020. View Article : Google Scholar : PubMed/NCBI

El-Arabey AA, Alkhalil SS, Al-Shouli ST, Awadalla ME, Alhamdi HW, Almanaa TN, Mohamed SSEM and Abdalla M: Revisiting macrophages in ovarian cancer microenvironment: Development, function and interaction. Med Oncol. 40:1422023. View Article : Google Scholar : PubMed/NCBI

Larionova I, Tuguzbaeva G, Ponomaryova A, Stakheyeva M, Cherdyntseva N, Pavlov V, Choinzonov E and Kzhyshkowska J: Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers. Front Oncol. 10:5665112020. View Article : Google Scholar : PubMed/NCBI

Miyamoto T, Murphy B and Zhang N: Intraperitoneal metastasis of ovarian cancer: New insights on resident macrophages in the peritoneal cavity. Front Immunol. 14:11046942023. View Article : Google Scholar : PubMed/NCBI

Yin M, Shen J, Yu S, Fei J, Zhu X, Zhao J, Zhai L, Sadhukhan A and Zhou J: Tumor-associated macrophages (TAMs): A critical activator in ovarian cancer metastasis. Onco Targets Ther. 12:8687–8699. 2019. View Article : Google Scholar : PubMed/NCBI

Jazwinska DE, Kulawiec DG and Zervantonakis IK: Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment. Am J Physiol Cell Physiol. 325:C721–C730. 2023. View Article : Google Scholar : PubMed/NCBI

Klymenko Y, Johnson J, Bos B, Lombard R, Campbell L, Loughran E and Stack MS: Heterogeneous cadherin expression and multicellular aggregate dynamics in ovarian cancer dissemination. Neoplasia. 19:549–563. 2017. View Article : Google Scholar : PubMed/NCBI

Ford CE, Werner B, Hacker NF and Warton K: The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 123:9–16. 2020. View Article : Google Scholar : PubMed/NCBI

Habanjar O, Diab-Assaf M, Caldefie-Chezet F and Delort L: 3D cell culture systems: Tumor application, advantages, and disadvantages. Int J Mol Sci. 22:122002021. View Article : Google Scholar : PubMed/NCBI

Matte I, Legault CM, Garde-Granger P, Laplante C, Bessette P, Rancourt C and Piché A: Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions. Clin Exp Metastasis. 33:839–852. 2016. View Article : Google Scholar : PubMed/NCBI

Xu S, Yang Y, Dong L, Qiu W, Yang L, Wang X and Liu L: Construction and characteristics of an E-cadherin-related three-dimensional suspension growth model of ovarian cancer. Sci Rep. 4:56462014. View Article : Google Scholar : PubMed/NCBI

Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, et al: Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 68:2329–2339. 2008. View Article : Google Scholar : PubMed/NCBI

Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR Jr, Ruff LE and Skubitz AP: Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol. 159:2071–2080. 2001. View Article : Google Scholar : PubMed/NCBI

Han Q, Huang B, Huang Z, Cai J, Gong L, Zhang Y, Jiang J, Dong W and Wang Z: Tumor cell-fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer. Int J Mol Med. 44:2245–2255. 2019.PubMed/NCBI

Hassn Mesrati M, Syafruddin SE, Mohtar MA and Syahir A: CD44: A multifunctional mediator of cancer progression. Biomolecules. 11:18502021. View Article : Google Scholar : PubMed/NCBI

Chen MW, Yang ST, Chien MH, Hua KT, Wu CJ, Hsiao SM, Lin H, Hsiao M, Su JL and Wei LH: The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer. Cancer Res. 77:1955–1967. 2017. View Article : Google Scholar : PubMed/NCBI

Li SS, Ma J and Wong AST: Chemoresistance in ovarian cancer: Exploiting cancer stem cell metabolism. J Gynecol Oncol. 29:e322018. View Article : Google Scholar : PubMed/NCBI

Casagrande N, Borghese C, Agostini F, Durante C, Mazzucato M, Colombatti A and Aldinucci D: In ovarian cancer multicellular spheroids, platelet releasate promotes growth, expansion of ALDH+ and CD133+ cancer stem cells, and protection against the cytotoxic effects of cisplatin, carboplatin and paclitaxel. Int J Mol Sci. 22:30192021. View Article : Google Scholar : PubMed/NCBI

Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD and Matei D: β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene. 34:2297–2308. 2015. View Article : Google Scholar

Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, et al: Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 39:611–621. 2013. View Article : Google Scholar : PubMed/NCBI

Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S and Kikkawa F: Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res. 11:2686–2694. 2005. View Article : Google Scholar : PubMed/NCBI

Zhang Q, Yu S, Lam MMT, Poon TCW, Sun L, Jiao Y, Wong AST and Lee LTO: Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress. J Exp Clin Cancer Res. 38:1162019. View Article : Google Scholar : PubMed/NCBI

Adeshakin FO, Adeshakin AO, Afolabi LO, Yan D, Zhang G and Wan X: Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming. Front Oncol. 11:6265772021. View Article : Google Scholar : PubMed/NCBI

Frisch SM and Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol. 13:555–562. 2001. View Article : Google Scholar : PubMed/NCBI

Grossmann J: Molecular mechanisms of 'detachment-induced apoptosis-Anoikis'. Apoptosis. 7:247–260. 2002. View Article : Google Scholar : PubMed/NCBI

Taddei ML, Giannoni E, Fiaschi T and Chiarugi P: Anoikis: An emerging hallmark in health and diseases. J Pathol. 226:380–393. 2012. View Article : Google Scholar

Cai Q, Yan L and Xu Y: Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells. Oncogene. 34:3315–3324. 2015. View Article : Google Scholar :

Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI

Park JT, Shih IeM and Wang TL: Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res. 68:8852–8860. 2008. View Article : Google Scholar : PubMed/NCBI

Brown CW, Brodsky AS and Freiman RN: Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2. Mol Cancer Res. 13:78–85. 2015. View Article : Google Scholar :

Tang MKS, Zhou HY, Yam JW and Wong AS: c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia. 12:128–138. 2010. View Article : Google Scholar : PubMed/NCBI

Lopez A, Reyna DE, Gitego N, Kopp F, Zhou H, Miranda-Roman MA, Nordstrøm LU, Narayanagari SR, Chi P, Vilar E, et al: Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nat Commun. 13:11992022. View Article : Google Scholar : PubMed/NCBI

Mei H, Nakatsu MN, Baclagon ER and Deng SX: Frizzled 7 maintains the undifferentiated state of human limbal stem/progenitor cells. Stem Cells. 32:938–945. 2014. View Article : Google Scholar

Condello S, Sima L, Ivan C, Cardenas H, Schiltz G, Mishra RK and Matei D: Tissue tranglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche. Cancer Res. 78:2990–3001. 2018. View Article : Google Scholar : PubMed/NCBI

Qin Q, Xu Y, He T, Qin C and Xu J: Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 22:90–106. 2012. View Article : Google Scholar :

Tan M, Asad M, Heong V, Wong MK, Tan TZ, Ye J, Kuay KT, Thiery JP, Scott C and Huang RY: The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. Mol Oncol. 13:757–780. 2019. View Article : Google Scholar :

Motohara T, Masuda K, Morotti M, Zheng Y, El-Sahhar S, Chong KY, Wietek N, Alsaadi A, Carrami EM, Hu Z, et al: An evolving story of the metastatic voyage of ovarian cancer cells: Cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene. 38:2885–2898. 2019. View Article : Google Scholar :

Dai ZY, Jin SM, Luo HQ, Leng HL and Fang JD: LncRNA HOTAIR regulates anoikis-resistance capacity and spheroid formation of ovarian cancer cells by recruiting EZH2 and influencing H3K27 methylation. Neoplasma. 68:509–518. 2021. View Article : Google Scholar : PubMed/NCBI

Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, Giannakakis A, Poulos N, O'Brien-Jenkins A, Katsaros D, et al: Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res. 13:5314–5321. 2007. View Article : Google Scholar : PubMed/NCBI

Dong L and Hui L: HOTAIR promotes proliferation, migration, and invasion of ovarian cancer SKOV3 cells through regulating PIK3R3. Med Sci Monit. 22:325–331. 2016. View Article : Google Scholar : PubMed/NCBI

Dolinschek R, Hingerl J, Benge A, Zafiu C, Schüren E, Ehmoser EK, Lössner D and Reuning U: Constitutive activation of integrin αvβ3 contributes to anoikis resistance of ovarian cancer cells. Mol Oncol. 15:503–522. 2021. View Article : Google Scholar

Yu X, Liu L, Cai B, He Y and Wan X: Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci. 99:543–552. 2008. View Article : Google Scholar : PubMed/NCBI

Carduner L, Picot CR, Leroy-Dudal J, Blay L, Kellouche S and Carreiras F: Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. Exp Cell Res. 320:329–342. 2014. View Article : Google Scholar

Kim S, Kim S, Kim J, Kim B, Kim SI, Kim MA, Kwon S and Song YS: Evaluating tumor evolution via genomic profiling of individual tumor spheroids in a malignant ascites. Sci Rep. 8:127242018. View Article : Google Scholar : PubMed/NCBI

Allen HJ, Porter C, Gamarra M, Piver MS and Johnson EA: Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions. Exp Cell Biol. 55:194–208. 1987.PubMed/NCBI

Azharuddin M, Roberg K, Dhara AK, Jain MV, Darcy P, Hinkula J, Slater NKH and Patra HK: Dissecting multi drug resistance in head and neck cancer cells using multicellular tumor spheroids. Sci Rep. 9:200662019. View Article : Google Scholar : PubMed/NCBI

Świerczewska M, Sterzyńska K, Ruciński M, Andrzejewska M, Nowicki M and Januchowski R: The response and resistance to drugs in ovarian cancer cell lines in 2D monolayers and 3D spheroids. Biomed Pharmacother. 165:1151522023. View Article : Google Scholar : PubMed/NCBI

Sun Y, Li S, Yang L, Zhang D, Zhao Z, Gao J and Liu L: CDC25A facilitates chemo-resistance in ovarian cancer multicellular spheroids by promoting E-cadherin expression and arresting cell cycles. J Cancer. 10:2874–2884. 2019. View Article : Google Scholar : PubMed/NCBI

Shen T and Huang S: The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem. 12:631–639. 2012. View Article : Google Scholar : PubMed/NCBI

Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, Lissoni AA, Mangioni C and D'Incalci M: Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 20:4835–4840. 2000.

Green SK, Francia G, Isidoro C and Kerbel RS: Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther. 3:149–159. 2004. View Article : Google Scholar : PubMed/NCBI

Lim GH, An JH, Park SM, Youn GH, Oh YI, Seo KW and Youn HY: Macrophage induces anti-cancer drug resistance in canine mammary gland tumor spheroid. Sci Rep. 13:103942023. View Article : Google Scholar : PubMed/NCBI

Makhija S, Taylor DD, Gibb RK and Gerçel-Taylor C: Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Int J Oncol. 14:515–521. 1999.PubMed/NCBI

Yvon AM, Wadsworth P and Jordan MA: Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell. 10:947–959. 1999. View Article : Google Scholar : PubMed/NCBI

Makovec T: Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol. 53:148–158. 2019. View Article : Google Scholar : PubMed/NCBI

Kwon MJ and Shin YK: Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci. 14:6624–6648. 2013. View Article : Google Scholar : PubMed/NCBI

Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD and Odunsi K: Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One. 9:e849412014. View Article : Google Scholar : PubMed/NCBI

McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, Chin KT, Partridge JC, Poole BB, Cheng KH, et al: Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA. 109:E2939–E2948. 2012. View Article : Google Scholar : PubMed/NCBI

Kang H, Jeong JY, Song JY, Kim TH, Kim G, Huh JH, Kwon AY, Jung SG and An HJ: Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells. Mol Carcinog. 55:1196–1209. 2016. View Article : Google Scholar

van Baal JOAM, Van de Vijver KK, Nieuwland R, van Noorden CJF, van Driel WJ, Sturk A, Kenter GG, Rikkert LG and Lok CAR: The histophysiology and pathophysiology of the peritoneum. Tissue Cell. 49:95–105. 2017. View Article : Google Scholar

Nakamura M, Ono YJ, Kanemura M, Tanaka T, Hayashi M, Terai Y and Ohmichi M: Hepatocyte growth factor secreted by ovarian cancer cells stimulates peritoneal implantation via the mesothelial-mesenchymal transition of the peritoneum. Gynecol Oncol. 139:345–354. 2015. View Article : Google Scholar : PubMed/NCBI

Yousefi M, Dehghani S, Nosrati R, Ghanei M, Salmaninejad A, Rajaie S, Hasanzadeh M and Pasdar A: Current insights into the metastasis of epithelial ovarian cancer-hopes and hurdles. Cell Oncol (Dordr). 43:515–538. 2020. View Article : Google Scholar : PubMed/NCBI

Cui L, Johkura K, Liang Y, Teng R, Ogiwara N, Okouchi Y, Asanuma K and Sasaki K: Biodefense function of omental milky spots through cell adhesion molecules and leukocyte proliferation. Cell Tissue Res. 310:321–330. 2002. View Article : Google Scholar : PubMed/NCBI

Niedbala MJ, Crickard K and Bernacki RJ: Interactions of human ovarian tumor cells with human mesothelial cells grown on extracellular matrix. An in vitro model system for studying tumor cell adhesion and invasion. Exp Cell Res. 160:499–513. 1985. View Article : Google Scholar : PubMed/NCBI

Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, Danuser G, Ince TA and Brugge JS: Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 1:144–157. 2011. View Article : Google Scholar

Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y and Ottensmeier C: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 53:3830–3838. 1993.PubMed/NCBI

Witz CA, Montoya-Rodriguez IA, Cho S, Centonze VE, Bonewald LF and Schenken RS: Composition of the extracellular matrix of the peritoneum. J Soc Gynecol Investig. 8:299–304. 2001. View Article : Google Scholar : PubMed/NCBI

Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr and Skubitz AP: Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 93:170–181. 2004. View Article : Google Scholar : PubMed/NCBI

Burleson KM, Boente MP, Pambuccian SE and Skubitz AP: Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med. 4:62006. View Article : Google Scholar : PubMed/NCBI

Moser TL, Pizzo SV, Bafetti LM, Fishman DA and Stack MS: Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer. 67:695–701. 1996. View Article : Google Scholar : PubMed/NCBI

Shield K, Riley C, Quinn MA, Rice GE, Ackland ML and Ahmed N: Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog. 6:112007. View Article : Google Scholar : PubMed/NCBI

Gupta V, Yull F and Khabele D: Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy. Cancers (Basel). 10:3662018. View Article : Google Scholar : PubMed/NCBI

Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J and Harris AL: Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56:4625–4629. 1996.PubMed/NCBI

Lewis JS, Landers RJ, Underwood JC, Harris AL and Lewis CE: Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol. 192:150–158. 2000. View Article : Google Scholar : PubMed/NCBI

Shibuya M: Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 153:13–19. 2013. View Article : Google Scholar

Han KY, Kim CW, Lee TH, Son Y and Kim J: CCL23 up-regulates expression of KDR/Flk-1 and potentiates VEGF-induced proliferation and migration of human endothelial cells. Biochem Biophys Res Commun. 382:124–128. 2009. View Article : Google Scholar : PubMed/NCBI

Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB and Reinthaller A: Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 103:512–517. 2006. View Article : Google Scholar : PubMed/NCBI

Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD and Jaffe RB: Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 9:5721–5728. 2003.PubMed/NCBI

Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, et al: Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res. 68:1100–1109. 2008. View Article : Google Scholar : PubMed/NCBI

Zhang S, Xie B, Wang L, Yang H, Zhang H, Chen Y, Wang F, Liu C and He H: Macrophage-mediated vascular permeability via VLA4/VCAM1 pathway dictates ascites development in ovarian cancer. J Clin Invest. 131:e1403152021. View Article : Google Scholar :

Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schwörer AM, Wagner U, Müller-Brüsselbach S and Müller R: Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 134:32–42. 2014. View Article : Google Scholar :

Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, Lin C, Iruela-Arispe ML, Dorigo O and Wu L: Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res. 75:4742–4752. 2015. View Article : Google Scholar : PubMed/NCBI

Clancy JL, Henderson MJ, Russell AJ, Anderson DW, Bova RJ, Campbell IG, Choong DY, Macdonald GA, Mann GJ, Nolan T, et al: EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene. 22:5070–5081. 2003. View Article : Google Scholar : PubMed/NCBI

Shearer RF, Iconomou M, Watts CK and Saunders DN: Functional roles of the E3 ubiquitin ligase UBR5 in cancer. Mol Cancer Res. 13:1523–1532. 2015. View Article : Google Scholar : PubMed/NCBI

Tang M, Liu B, Bu X and Zhao P: Cross-talk between ovarian cancer cells and macrophages through periostin promotes macrophage recruitment. Cancer Sci. 109:1309–1318. 2018. View Article : Google Scholar : PubMed/NCBI

Durlanik S, Fundel-Clemens K, Viollet C, Huber HJ, Lenter M, Kitt K and Pflanz S: CD276 is an important player in macrophage recruitment into the tumor and an upstream regulator for PAI-1. Sci Rep. 11:148492021. View Article : Google Scholar : PubMed/NCBI

Worzfeld T, Finkernagel F, Reinartz S, Konzer A, Adhikary T, Nist A, Stiewe T, Wagner U, Looso M, Graumann J and Müller R: Proteotranscriptomics reveal signaling networks in the ovarian cancer microenvironment. Mol Cell Proteomics. 17:270–289. 2018. View Article : Google Scholar :

Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K and Gotoh Y: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275:90–94. 1997. View Article : Google Scholar : PubMed/NCBI

Yin M, Zhou HJ, Zhang J, Lin C, Li H, Li X, Li Y, Zhang H, Breckenridge DG, Ji W and Min W: ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis. JCI Insight. 2:e918282017. View Article : Google Scholar : PubMed/NCBI

Sica A and Mantovani A: Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI

Mills CD, Kincaid K, Alt JM, Heilman MJ and Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 164:6166–6173. 2000. View Article : Google Scholar : PubMed/NCBI

Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25:677–686. 2004. View Article : Google Scholar : PubMed/NCBI

Wen Y and Crowley SD: The varying roles of macrophages in kidney injury and repair. Curr Opin Nephrol Hypertens. 29:286–292. 2020. View Article : Google Scholar : PubMed/NCBI

Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR, et al: Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest. 112:197–208. 2003. View Article : Google Scholar : PubMed/NCBI

Gao J, Liang Y and Wang L: Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front Immunol. 13:8887132022. View Article : Google Scholar : PubMed/NCBI

Wan C, Sun Y, Tian Y, Lu L, Dai X, Meng J, Huang J, He Q, Wu B, Zhang Z, et al: Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci Adv. 6:eaay97892020. View Article : Google Scholar : PubMed/NCBI

Shu Y and Cheng P: Targeting tumor-associated macrophages for cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 1874:1884342020. View Article : Google Scholar : PubMed/NCBI

He J, Yin P and Xu K: Effect and molecular mechanisms of traditional Chinese medicine on tumor targeting tumor-associated macrophages. Drug Des Devel Ther. 14:907–919. 2020. View Article : Google Scholar : PubMed/NCBI

Macciò A, Gramignano G, Cherchi MC, Tanca L, Melis L and Madeddu C: Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. Sci Rep. 10:60962020. View Article : Google Scholar : PubMed/NCBI

Guiducci C, Vicari AP, Sangaletti S, Trinchieri G and Colombo MP: Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65:3437–3446. 2005. View Article : Google Scholar : PubMed/NCBI

Capellero S, Erriquez J, Battistini C, Porporato R, Scotto G, Borella F, Di Renzo MF, Valabrega G and Olivero M: Ovarian cancer cells in ascites form aggregates that display a hybrid epithelial-mesenchymal phenotype and allows survival and proliferation of metastasizing cells. Int J Mol Sci. 23:8332022. View Article : Google Scholar : PubMed/NCBI

Sun S, Pan X, Zhao L, Zhou J, Wang H and Sun Y: The expression and relationship of CD68-tumor-associated macrophages and microvascular density with the prognosis of patients with laryngeal squamous cell carcinoma. Clin Exp Otorhinolaryngol. 9:270–277. 2016. View Article : Google Scholar : PubMed/NCBI

Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, et al: STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response. Pharmacol Res. 182:1063112022. View Article : Google Scholar : PubMed/NCBI

Liang R, Chen X, Chen L, Wan F, Chen K, Sun Y and Zhu X: STAT3 signaling in ovarian cancer: A potential therapeutic target. J Cancer. 11:837–848. 2020. View Article : Google Scholar : PubMed/NCBI

Takaishi K, Komohara Y, Tashiro H, Ohtake H, Nakagawa T, Katabuchi H and Takeya M: Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 101:2128–2136. 2010. View Article : Google Scholar : PubMed/NCBI

Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A and Tahara H: Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA. 108:12425–12430. 2011. View Article : Google Scholar : PubMed/NCBI

Raghavan S, Mehta P, Xie Y, Lei YL and Mehta G: Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer. 7:1902019. View Article : Google Scholar : PubMed/NCBI

Ruffell B and Coussens LM: Macrophages and therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015. View Article : Google Scholar : PubMed/NCBI

Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, Gong K, Liu F, Duan Y and Li H: Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnology. 20:502022. View Article : Google Scholar : PubMed/NCBI

Li H, Luo F, Jiang X, Zhang W, Xiang T, Pan Q, Cai L, Zhao J, Weng D, Li Y, et al: CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. J Immunother Cancer. 10:e0040292022. View Article : Google Scholar : PubMed/NCBI

Ding L, Wang Q, Martincuks A, Kearns MJ, Jiang T, Lin Z, Cheng X, Qian C, Xie S, Kim HJ, et al: STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. J Immunother Cancer. 11:e0056272023. View Article : Google Scholar : PubMed/NCBI

Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 109:6662–6667. 2012. View Article : Google Scholar : PubMed/NCBI

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, et al: First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 37:946–953. 2019. View Article : Google Scholar : PubMed/NCBI

Huang Y, Lv SQ, Liu PY, Ye ZL, Yang H, Li LF, Zhu HL, Wang Y, Cui LZ, Jiang DQ, et al: A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. Mol Oncol. 14:657–668. 2020. View Article : Google Scholar : PubMed/NCBI

Batchu RB, Gruzdyn OV, Kolli BK, Dachepalli R, Umar PS, Rai SK, Singh N, Tavva PS, Weaver DW and Gruber SA: IL-10 signaling in the tumor microenvironment of ovarian cancer. Adv Exp Med Biol. 1290:51–65. 2021. View Article : Google Scholar : PubMed/NCBI

McKarns SC, Schwartz RH and Kaminski NE: Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol. 172:4275–4284. 2004. View Article : Google Scholar : PubMed/NCBI

Wertel I, Surówka J, Polak G, Barczyński B, Bednarek W, Jakubowicz-Gil J, Bojarska-Junak A and Kotarski J: Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumour Biol. 36:4811–4817. 2015. View Article : Google Scholar : PubMed/NCBI

Kamat K, Krishnan V and Dorigo O: Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer. Br J Cancer. 127:1026–1033. 2022. View Article : Google Scholar : PubMed/NCBI

Noy R and Pollard JW: Tumor-associated macrophages: From mechanisms to therapy. Immunity. 41:49–61. 2014. View Article : Google Scholar : PubMed/NCBI

Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K and Chen L: B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2:269–274. 2001. View Article : Google Scholar : PubMed/NCBI

Miyamoto T, Murakami R, Hamanishi J, Tanigaki K, Hosoe Y, Mise N, Takamatsu S, Mise Y, Ukita M, Taki M, et al: B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression. Cancer Immunol Res. 10:56–69. 2022. View Article : Google Scholar

Liu Z, Jin K, Zeng H, Shao F, Chang Y, Wang Y, Xu L, Wang Z, Cui X, Zhu Y and Xu J: B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer. Eur J Cancer. 171:133–142. 2022. View Article : Google Scholar : PubMed/NCBI

Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, et al: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 203:871–881. 2006. View Article : Google Scholar : PubMed/NCBI

Carroll MJ, Fogg KC, Patel HA, Krause HB, Mancha AS, Patankar MS, Weisman PS, Barroilhet L and Kreeger PK: Alternatively-activated macrophages upregulate mesothelial expression of P-selectin to enhance adhesion of ovarian cancer cells. Cancer Res. 78:3560–3573. 2018. View Article : Google Scholar : PubMed/NCBI

Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM and Drew AF: Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 67:5708–5716. 2007. View Article : Google Scholar : PubMed/NCBI

Fogg KC, Olson WR, Miller JN, Khan A, Renner C, Hale I, Weisman PS and Kreeger PK: Alternatively activated macrophage-derived secretome stimulates ovarian cancer spheroid spreading through a JAK2/STAT3 pathway. Cancer Lett. 458:92–101. 2019. View Article : Google Scholar : PubMed/NCBI

Zeng XY, Xie H, Yuan J, Jiang XY, Yong JH, Zeng D, Dou YY and Xiao SS: M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. Cancer Biol Ther. 20:956–966. 2019. View Article : Google Scholar : PubMed/NCBI

Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, et al: Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 23:249–262. 2013. View Article : Google Scholar : PubMed/NCBI

Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ, Puchalski TA, Balkwill F, et al: A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol. 71:1041–1050. 2013. View Article : Google Scholar : PubMed/NCBI

Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, et al: Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. Ther Adv Med Oncol. 11:17588359198542382019. View Article : Google Scholar : PubMed/NCBI

Zeng Y, Li B, Liang Y, Reeves PM, Qu X, Ran C, Liu Q, Callahan MV, Sluder AE, Gelfand JA, et al: Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 33:6596–6608. 2019. View Article : Google Scholar : PubMed/NCBI

Wanderley CW, Colón DF, Luiz JPM, Oliveira FF, Viacava PR, Leite CA, Pereira JA, Silva CM, Silva CR, Silva RL, et al: Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 Profile in a TLR4-dependent manner. Cancer Res. 78:5891–5900. 2018. View Article : Google Scholar : PubMed/NCBI

Zhang Q, Li Y, Miao C, Wang Y, Xu Y, Dong R, Zhang Z, Griffin BB, Yuan C, Yan S, et al: Anti-angiogenesis effect of Neferine via regulating autophagy and polarization of tumor-associated macrophages in high-grade serous ovarian carcinoma. Cancer Lett. 432:144–155. 2018. View Article : Google Scholar : PubMed/NCBI

Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, Holland EC and Stephan MT: Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 10:39742019. View Article : Google Scholar : PubMed/NCBI

Chen D, Xie J, Fiskesund R, Dong W, Liang X, Lv J, Jin X, Liu J, Mo S, Zhang T, et al: Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 9:8732018. View Article : Google Scholar : PubMed/NCBI

Bellora F, Castriconi R, Dondero A, Pessino A, Nencioni A, Liggieri G, Moretta L, Mantovani A, Moretta A and Bottino C: TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. Eur J Immunol. 44:1814–1822. 2014. View Article : Google Scholar : PubMed/NCBI

Ma L, Zhu M, Gai J, Li G, Chang Q, Qiao P, Cao L, Chen W, Zhang S and Wan Y: Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. J Nanobiotechnology. 18:122020. View Article : Google Scholar : PubMed/NCBI

Rakina M, Kazakova A, Villert A, Kolomiets L and Larionova I: Spheroid formation and peritoneal metastasis in ovarian cancer: The role of stromal and immune components. Int J Mol Sci. 23:62152022. View Article : Google Scholar : PubMed/NCBI

Long L, Yin M and Min W: 3D co-culture system of tumor-associated macrophages and ovarian cancer cells. Bio Protoc. 8:e28152018.PubMed/NCBI